Mixed reactions to latest coronary stenting study
Published date : 30 August 2012
Article date : 30 August 2012
More findings and analysis from St. Jude Medical's Fame II trial, studying fractional flow reserve-directing coronary stenting, have been made available.
According to the manufacture, patients who received percutaneous coronary intervention in addition to drug therapy were better off than patients who took drugs alone. However, a Mass Device article reports that some questions on the results have been raised in the market place.
The article goes on to say that patients in one area of the study received percutaneous coronary intervention guided by fractional flow reserve technology to measure and identify blood vessel narrowings and determine which are obstructing blood flow to the heart. Those patients also received "optimal medical therapy," an anti-platelet and beta blocker drug regimen.
Source: Mass Device, 28th August 2012
Read the full article here
